nach oben

26.03.2024 | REVIEW

Glioblastoma stem cell metabolism and immunity

verfasst von: Joseph Hawly, Micaela G. Murcar, Alejandro Schcolnik-Cabrera, Mark E. Issa

Erschienen in: Cancer and Metastasis Reviews

Einloggen, um Zugang zu erhalten

Abstract

Despite enormous efforts being invested in the development of novel therapies for brain malignancies, there remains a dire need for effective treatments, particularly for pediatric glioblastomas. Their poor prognosis has been attributed to the fact that conventional therapies target tumoral cells, but not glioblastoma stem cells (GSCs). GSCs are characterized by self-renewal, tumorigenicity, poor differentiation, and resistance to therapy. These characteristics represent the fundamental tools needed to recapitulate the tumor and result in a relapse. The mechanisms by which GSCs alter metabolic cues and escape elimination by immune cells are discussed in this article, along with potential strategies to harness effector immune cells against GSCs. As cellular immunotherapy is making significant advances in a variety of cancers, leveraging this underexplored reservoir may result in significant improvements in the treatment options for brain malignancies.

Alvarado, A. G., Thiagarajan, P. S., Mulkearns-Hubert, E. E., Silver, D. J., Hale, J. S., Alban, T. J., … Lathia, J. D. (2017). Glioblastoma cancer stem cells evade innate immune suppression of self-renewal through reduced TLR4 expression. Cell Stem Cell, 20(4), 450–461.e4. https://doi.org/10.1016/j.stem.2016.12.001

Garnier, D., Renoult, O., Alves-Guerra, M.-C., Paris, F., & Pecqueur, C. (2019). Glioblastoma stem-like cells, metabolic strategy to kill a challenging target. Frontiers in Oncology, 9, 118. https://doi.org/10.3389/fonc.2019.00118CrossRefPubMedPubMedCentral

Esparza, R., Azad, T. D., Feroze, A. H., Mitra, S. S., & Cheshier, S. H. (2015). Glioblastoma stem cells and stem cell-targeting immunotherapies. Journal of Neuro-Oncology, 123(3), 449–457. https://doi.org/10.1007/s11060-015-1729-xCrossRefPubMed

Geller, M. A., & Miller, J. S. (2011). Use of allogeneic NK cells for cancer immunotherapy. Immunotherapy, 3(12), 1445–1459. https://doi.org/10.2217/imt.11.131CrossRefPubMed

National Cancer Institute. (n.d.). Surveillance, Epidemiology, and End Results (SEER) Program Explorer Application. Retrieved April 5, 2023, from https://seer.cancer.gov/statistics-network/explorer/application.html?site=661&data_type=5&graph_type=12&compareBy=sex&chk_sex_1=1&chk_sex_3=3&chk_sex_2=2&series=9&race=1&age_range=15&prev_duration=1&advopt_precision=1&hdn_view=1

Lam, S., Lin, Y., Zinn, P., Su, J., & Pan, I.-W. (2018). Patient and treatment factors associated with survival among pediatric glioblastoma patients: A Surveillance, Epidemiology, and End Results study. Journal of Clinical Neuroscience, 47, 285–293. https://doi.org/10.1016/j.jocn.2017.10.041CrossRefPubMed

Da, W., Xueli, C., Xiao, P., & Yian, X. (2020). Prognostic factors and survival prediction of pediatric glioblastomas: A population-based study. Turkish Neurosurgeryhttps://doi.org/10.5137/1019-5149.JTN.31915-20.2

Hardell, L., Carlberg, M., & Mild, K. H. (2006). Case-control study of the association between the use of cellular and cordless telephones and malignant brain tumors diagnosed during 2000–2003. Environmental Research, 100(2), 232–241. https://doi.org/10.1016/j.envres.2005.04.006CrossRefPubMed

INTERPHONE Study Group. (2010). Brain tumour risk in relation to mobile telephone use: Results of the INTERPHONE international case-control study. International Journal of Epidemiology, 39(3), 675–694. https://doi.org/10.1093/ije/dyq079CrossRef

10.

Lahkola, A., Auvinen, A., Raitanen, J., Schoemaker, M. J., Christensen, H. C., Feychting, M., … Salminen, T. (2007). Mobile phone use and risk of glioma in 5 North European countries. International Journal of Cancer, 120(8), 1769–1775. https://doi.org/10.1002/ijc.22503

11.

World Health Organisation. (2011, May 31). IARC classifies radiofrequency electromagnetic fields as possibly carcinogenic to humans. Retrieved July 5, 2023, from https://www.iarc.who.int/pressrelease/iarc-classifies-radiofrequency-electromagnetic-fields-as-possibly-carcinogenic-to-humans/

12.

Deltour, I., Poulsen, A. H., Johansen, C., Feychting, M., Johannesen, T. B., Auvinen, A., & Schüz, J. (2022). Time trends in mobile phone use and glioma incidence among males in the Nordic Countries, 1979–2016. Environment International, 168, 107487. https://doi.org/10.1016/j.envint.2022.107487CrossRefPubMedPubMedCentral

13.

Baker, S. J., Ellison, D. W., & Gutmann, D. H. (2016). Pediatric gliomas as neurodevelopmental disorders. Glia, 64(6), 879–895. https://doi.org/10.1002/glia.22945CrossRefPubMed

14.

Sturm, D., Witt, H., Hovestadt, V., Khuong-Quang, D.-A., Jones, D. T. W., Konermann, C., … Pfister, S. M. (2012). Hotspot mutations in H3F3A and IDH1 define distinct epigenetic and biological subgroups of glioblastoma. Cancer Cell, 22(4), 425–437. https://doi.org/10.1016/j.ccr.2012.08.024

15.

Janke, R., Iavarone, A. T., & Rine, J. (2017). Oncometabolite D-2-hydroxyglutarate enhances gene silencing through inhibition of specific H3K36 histone demethylases. eLife, 6. https://doi.org/10.7554/eLife.22451

16.

Zong, H., Parada, L. F., & Baker, S. J. (2015). Cell of origin for malignant gliomas and its implication in therapeutic development. Cold Spring Harbor Perspectives in Biology, 7(5), a020610. https://doi.org/10.1101/cshperspect.a020610CrossRefPubMedPubMedCentral

17.

Jones, C., & Baker, S. J. (2014). Unique genetic and epigenetic mechanisms driving paediatric diffuse high-grade glioma. Nature Reviews. Cancer, 14(10). https://doi.org/10.1038/nrc3811

18.

Ostrom, Q. T., Cioffi, G., Waite, K., Kruchko, C., & Barnholtz-Sloan, J. S. (2021). CBTRUS statistical report: Primary brain and other central nervous system tumors diagnosed in the United States in 2014–2018. Neuro-Oncology, 23(12 Suppl 2), iii1–iii105. https://doi.org/10.1093/neuonc/noab200

19.

Rowitch, D. H., & Kriegstein, A. R. (2010). Developmental genetics of vertebrate glial-cell specification. Nature, 468(7321), 214–222. https://doi.org/10.1038/nature09611CrossRefPubMed

20.

Takebayashi, H., & Ikenaka, K. (2015). Oligodendrocyte generation during mouse development. Glia, 63(8), 1350–1356. https://doi.org/10.1002/glia.22863CrossRefPubMed

21.

Yacob, M. S., & Johnston, D. L. (2016). Glioblastoma multiforme: A pediatric case series. Journal of Case Reports and Images in Oncology, 2, 18–22. https://doi.org/10.5348/Z10-2016-14-CS-5CrossRef

22.

Wilne, S., Collier, J., Kennedy, C., Koller, K., Grundy, R., & Walker, D. (2007). Presentation of childhood CNS tumours: A systematic review and meta-analysis. The Lancet Oncology, 8(8), 685–695. https://doi.org/10.1016/S1470-2045(07)70207-3CrossRefPubMed

23.

Das, K. K., Mehrotra, A., Nair, A. P., Kumar, S., Srivastava, A. K., Sahu, R. N., & Kumar, R. (2012). Pediatric glioblastoma: Clinico-radiological profile and factors affecting the outcome. Child’s Nervous System, 28(12), 2055–2062. https://doi.org/10.1007/s00381-012-1890-xCrossRefPubMed

24.

McKinnon, C., Nandhabalan, M., Murray, S. A., & Plaha, P. (2021). Glioblastoma: Clinical presentation, diagnosis, and management. BMJ, 374, n1560. https://doi.org/10.1136/bmj.n1560CrossRefPubMed

25.

Ozawa, M., Brennan, P. M., Zienius, K., Kurian, K. M., Hollingworth, W., Weller, D., … Ben-Shlomo, Y. (2019). The usefulness of symptoms alone or combined for general practitioners in considering the diagnosis of a brain tumour: A case-control study using the clinical practice research database (CPRD) (2000–2014). BMJ Open, 9(8), e029686. https://doi.org/10.1136/bmjopen-2019-029686

26.

Ideguchi, M., Kajiwara, K., Goto, H., Sugimoto, K., Nomura, S., Ikeda, E., & Suzuki, M. (2015). MRI findings and pathological features in early-stage glioblastoma. Journal of Neuro-Oncology, 123(2), 289–297. https://doi.org/10.1007/s11060-015-1797-yCrossRefPubMed

27.

Verburg, N., Hoefnagels, F. W. A., Barkhof, F., Boellaard, R., Goldman, S., Guo, J., … De Witt Hamer, P. C. (2017). Diagnostic accuracy of neuroimaging to delineate diffuse gliomas within the brain: A meta-analysis. AJNR: American Journal of Neuroradiology, 38(10), 1884–1891. https://doi.org/10.3174/ajnr.A5368

28.

Wen, P. Y., Macdonald, D. R., Reardon, D. A., Cloughesy, T. F., Sorensen, A. G., Galanis, E., … Chang, S. M. (2010). Updated response assessment criteria for high-grade gliomas: Response assessment in neuro-oncology working group. Journal of Clinical Oncology: Official Journal of the American Society of Clinical Oncology, 28(11), 1963–1972. https://doi.org/10.1200/JCO.2009.26.3541

29.

van den Bent, M. J., Wefel, J. S., Schiff, D., Taphoorn, M. J. B., Jaeckle, K., Junck, L., … Jacobs, A. H. (2011). Response assessment in neuro-oncology (a report of the RANO group): Assessment of outcome in trials of diffuse low-grade gliomas. The Lancet. Oncology, 12(6), 583–593. https://doi.org/10.1016/S1470-2045(11)70057-2

30.

Cohen, K. J., Heideman, R. L., Zhou, T., Holmes, E. J., Lavey, R. S., Bouffet, E., & Pollack, I. F. (2011). Temozolomide in the treatment of children with newly diagnosed diffuse intrinsic pontine gliomas: A report from the Children’s Oncology Group. Neuro-Oncology, 13(4), 410–416. https://doi.org/10.1093/neuonc/noq205CrossRefPubMedPubMedCentral

31.

Cohen, K. J., Pollack, I. F., Zhou, T., Buxton, A., Holmes, E. J., Burger, P. C., … Heideman, R. L. (2011). Temozolomide in the treatment of high-grade gliomas in children: A report from the Children’s Oncology Group. Neuro-Oncology, 13(3), 317–323. https://doi.org/10.1093/neuonc/noq191

32.

Warren, K. E. (2012). Diffuse intrinsic pontine glioma: Poised for progress. Frontiers in Oncology, 2, 205. https://doi.org/10.3389/fonc.2012.00205CrossRefPubMedPubMedCentral

33.

Tallman, M. M., Zalenski, A. A., & Venere, M. (2021). Cancer stem cells in pediatric brain tumors. In W. Debinski (Ed.), Gliomas. Brisbane (AU): Exon Publications. Retrieved from http://www.ncbi.nlm.nih.gov/books/NBK570697/

34.

Rich, J. N., & Bao, S. (2007). Chemotherapy and cancer stem cells. Cell Stem Cell, 1(4), 353–355. https://doi.org/10.1016/j.stem.2007.09.011CrossRefPubMed

35.

Visvader, J. E., & Lindeman, G. J. (2008). Cancer stem cells in solid tumours: Accumulating evidence and unresolved questions. Nature Reviews Cancer, 8(10), 755–768. https://doi.org/10.1038/nrc2499CrossRefPubMed

36.

Taylor, M. D., Poppleton, H., Fuller, C., Su, X., Liu, Y., Jensen, P., … Gilbertson, R. J. (2005). Radial glia cells are candidate stem cells of ependymoma. Cancer Cell, 8(4), 323–335. https://doi.org/10.1016/j.ccr.2005.09.001

37.

Milde, T., Kleber, S., Korshunov, A., Witt, H., Hielscher, T., Koch, P., … Witt, O. (2011). A novel human high-risk ependymoma stem cell model reveals the differentiation-inducing potential of the histone deacetylase inhibitor Vorinostat. Acta Neuropathologica, 122(5), 637–650. https://doi.org/10.1007/s00401-011-0866-3

38.

Huang, G.-H., Xu, Q.-F., Cui, Y.-H., Li, N., Bian, X.-W., & Lv, S.-Q. (2016). Medulloblastoma stem cells: Promising targets in medulloblastoma therapy. Cancer Science, 107(5), 583–589. https://doi.org/10.1111/cas.12925CrossRefPubMedPubMedCentral

39.

Sun, Y., Xu, C., Pan, C., Chen, X., Geng, Y., Wu, Y., … Zhang, L. (2019). Diffuse intrinsic pontine gliomas exhibit cell biological and molecular signatures of fetal hindbrain-derived neural progenitor cells. Neuroscience Bulletin, 35(2), 216–224. https://doi.org/10.1007/s12264-018-00329-6

40.

Filbin, M. G., Tirosh, I., Hovestadt, V., Shaw, M. L., Escalante, L. E., Mathewson, N. D., … Suvà, M. L. (2018). Developmental and oncogenic programs in H3K27M gliomas dissected by single-cell RNA-seq. Science, 360(6386), 331–335. https://doi.org/10.1126/science.aao4750

41.

Friedman, G. K., Raborn, J., Kelly, V. M., Cassady, K. A., Markert, J. M., & Gillespie, G. Y. (2013). Pediatric glioma stem cells: Biologic strategies for oncolytic HSV virotherapy. Frontiers in Oncology, 3, 28. https://doi.org/10.3389/fonc.2013.00028CrossRefPubMedPubMedCentral

42.

Abou-Antoun, T. J., Hale, J. S., Lathia, J. D., & Dombrowski, S. M. (2017). Brain cancer stem cells in adults and children: Cell biology and therapeutic implications. Neurotherapeutics, 14(2), 372–384. https://doi.org/10.1007/s13311-017-0524-0CrossRefPubMedPubMedCentral

43.

Siminovitch, L., McCulloch, E. A., & Till, J. E. (1963). The distribution of colony-forming cells among spleen colonies. Retrieved from https://tspace.library.utoronto.ca/handle/1807/2778

44.

Bifari, F., Pacelli, L., & Krampera, M. (2010). Immunological properties of embryonic and adult stem cells. World Journal of Stem Cells, 2(3), 50–60. https://doi.org/10.4252/wjsc.v2.i3.50CrossRefPubMedPubMedCentral

45.

Lombard, A., Digregorio, M., Delcamp, C., Rogister, B., Piette, C., & Coppieters, N. (2021). The subventricular zone, a hideout for adult and pediatric high-grade glioma stem cells. Frontiers in Oncology, 10. Retrieved from https://www.frontiersin.org/articles/https://doi.org/10.3389/fonc.2020.614930

46.

Skoda, J., & Veselska, R. (2018). Cancer stem cells in sarcomas: Getting to the stemness core. Biochimica et Biophysica Acta (BBA) - General Subjects, 1862(10), 2134–2139. https://doi.org/10.1016/j.bbagen.2018.07.006

47.

Genadry, K. C., Pietrobono, S., Rota, R., & Linardic, C. M. (2018). Soft tissue sarcoma cancer stem cells: An overview. Frontiers in Oncology, 8. Retrieved from https://www.frontiersin.org/articles/https://doi.org/10.3389/fonc.2018.00475

48.

Al-Hajj, M., Wicha, M. S., Benito-Hernandez, A., Morrison, S. J., & Clarke, M. F. (2003). Prospective identification of tumorigenic breast cancer cells. Proceedings of the National Academy of Sciences, 100(7), 3983–3988. https://doi.org/10.1073/pnas.0530291100CrossRef

49.

Collins, A. T., Berry, P. A., Hyde, C., Stower, M. J., & Maitland, N. J. (2005). Prospective identification of tumorigenic prostate cancer stem cells. Cancer Research, 65(23), 10946–10951. https://doi.org/10.1158/0008-5472.CAN-05-2018CrossRefPubMed

50.

Ho, M. M., Ng, A. V., Lam, S., & Hung, J. Y. (2007). Side population in human lung cancer cell lines and tumors is enriched with stem-like cancer cells. Cancer Research, 67(10), 4827–4833. https://doi.org/10.1158/0008-5472.CAN-06-3557CrossRefPubMed

51.

Ricci-Vitiani, L., Lombardi, D. G., Pilozzi, E., Biffoni, M., Todaro, M., Peschle, C., & De Maria, R. (2007). Identification and expansion of human colon-cancer-initiating cells. Nature, 445(7123), 111–115. https://doi.org/10.1038/nature05384CrossRefPubMed

52.

Eramo, A., Lotti, F., Sette, G., Pilozzi, E., Biffoni, M., Di Virgilio, A., … De Maria, R. (2008). Identification and expansion of the tumorigenic lung cancer stem cell population. Cell Death & Differentiation, 15(3), 504–514. https://doi.org/10.1038/sj.cdd.4402283

53.

Singh, S. K., Clarke, I. D., Terasaki, M., Bonn, V. E., Hawkins, C., Squire, J., & Dirks, P. B. (2003). Identification of a cancer stem cell in human brain tumors. Cancer Research, 63(18), 5821–5828.PubMed

54.

Gimple, R. C., Bhargava, S., Dixit, D., & Rich, J. N. (2019). Glioblastoma stem cells: Lessons from the tumor hierarchy in a lethal cancer. Genes & Development, 33(11–12), 591–609. https://doi.org/10.1101/gad.324301.119CrossRef

55.

Caretti, V., Bugiani, M., Freret, M., Schellen, P., Jansen, M., van Vuurden, D., … Monje, M. (2014). Subventricular spread of diffuse intrinsic pontine glioma. Acta Neuropathologica, 128(4), 605–607. https://doi.org/10.1007/s00401-014-1307-x

56.

Hemmati, H. D., Nakano, I., Lazareff, J. A., Masterman-Smith, M., Geschwind, D. H., Bronner-Fraser, M., & Kornblum, H. I. (2003). Cancerous stem cells can arise from pediatric brain tumors. Proceedings of the National Academy of Sciences, 100(25), 15178–15183. https://doi.org/10.1073/pnas.2036535100CrossRef

57.

Goffart, N., Lombard, A., Lallemand, F., Kroonen, J., Nassen, J., Di Valentin, E., … Rogister, B. (2017). CXCL12 mediates glioblastoma resistance to radiotherapy in the subventricular zone. Neuro-Oncology, 19(1), 66–77. https://doi.org/10.1093/neuonc/now136

58.

Valdés-Rives, S. A., Casique-Aguirre, D., Germán-Castelán, L., Velasco-Velázquez, M. A., & González-Arenas, A. (2017). Apoptotic signaling pathways in glioblastoma and therapeutic implications. BioMed Research International, 2017, 7403747. https://doi.org/10.1155/2017/7403747CrossRefPubMedPubMedCentral

59.

Morimoto, T., Nakazawa, T., Maeoka, R., Nakagawa, I., Tsujimura, T., & Matsuda, R. (2023). Natural killer cell-based immunotherapy against glioblastoma. International Journal of Molecular Sciences, 24(3), 2111. https://doi.org/10.3390/ijms24032111CrossRefPubMedPubMedCentral

60.

Brown, N. F., Carter, T. J., Ottaviani, D., & Mulholland, P. (2018). Harnessing the immune system in glioblastoma. British Journal of Cancer, 119(10), 1171–1181. https://doi.org/10.1038/s41416-018-0258-8CrossRefPubMedPubMedCentral

61.

Daubon, T., Hemadou, A., Romero Garmendia, I., & Saleh, M. (2020). Glioblastoma immune landscape and the potential of new immunotherapies. Frontiers in Immunology, 11, 585616. https://doi.org/10.3389/fimmu.2020.585616CrossRefPubMedPubMedCentral

62.

Pearson, J. R. D., Cuzzubbo, S., McArthur, S., Durrant, L. G., Adhikaree, J., Tinsley, C. J., … McArdle, S. E. B. (2020). Immune escape in glioblastoma multiforme and the adaptation of immunotherapies for treatment. Frontiers in Immunology, 11, 582106. https://doi.org/10.3389/fimmu.2020.582106

63.

Gravina, G. L., Colapietro, A., Mancini, A., Rossetti, A., Martellucci, S., Ventura, L., … Festuccia, C. (2022). ATX-101, a peptide targeting PCNA, has antitumor efficacy alone or in combination with radiotherapy in murine models of human glioblastoma. Cancers, 14(2), 289. https://doi.org/10.3390/cancers14020289

64.

Jiang, T., Wu, W., Zhang, H., Zhang, X., Zhang, D., Wang, Q., … Hang, C. (2017). High expression of B7-H6 in human glioma tissues promotes tumor progression. Oncotarget, 8(23), 37435–37447. https://doi.org/10.18632/oncotarget.16391

65.

Ravindranath, M. H., Filippone, E. J., Devarajan, A., & Asgharzadeh, S. (2019). Enhancing natural killer and CD8+ T cell-mediated anticancer cytotoxicity and proliferation of CD8+ T cells with HLA-E monospecific monoclonal antibodies. Monoclonal Antibodies in Immunodiagnosis and Immunotherapy, 38(2), 38–59. https://doi.org/10.1089/mab.2018.0043CrossRefPubMedPubMedCentral

66.

Lupo, K. B., & Matosevic, S. (2020). CD155 immunoregulation as a target for natural killer cell immunotherapy in glioblastoma. Journal of Hematology & Oncology, 13(1), 76. https://doi.org/10.1186/s13045-020-00913-2CrossRef

67.

Chitadze, G., & Kabelitz, D. (2022). Immune surveillance in glioblastoma: Role of the NKG2D system and novel cell-based therapeutic approaches. Scandinavian Journal of Immunology, 96(2), e13201. https://doi.org/10.1111/sji.13201CrossRefPubMed

68.

Mitsutake, Y., Hiromatsu, Y., Saisho, M., Tokunaga, N., Ichikawa, Y., Kaji, M., & Irie, K. (1986). [Immunological assay of the CA-125 value in pleural effusion in various types of pleuritis--Its application as a differential diagnostic parameter of tuberculous or carcinomatous pleuritis]. Gan No Rinsho. Japan Journal of Cancer Clinics, 32(5), 453–457.

69.

Wiedemuth, R., Klink, B., Fujiwara, M., Schröck, E., Tatsuka, M., Schackert, G., & Temme, A. (2016). Janus face-like effects of Aurora B inhibition: Antitumoral mode of action versus induction of aneuploid progeny. Carcinogenesis, 37(10), 993–1003. https://doi.org/10.1093/carcin/bgw083CrossRefPubMed

70.

Barrow, A. D., Edeling, M. A., Trifonov, V., Luo, J., Goyal, P., Bohl, B., … Colonna, M. (2018). Natural killer cells control tumor growth by sensing a growth factor. Cell, 172(3), 534–548.e19. https://doi.org/10.1016/j.cell.2017.11.037

71.

Enderlin, M., Kleinmann, E. V., Struyf, S., Buracchi, C., Vecchi, A., Kinscherf, R., … Dinsart, C. (2009). TNF-alpha and the IFN-gamma-inducible protein 10 (IP-10/CXCL-10) delivered by parvoviral vectors act in synergy to induce antitumor effects in mouse glioblastoma. Cancer Gene Therapy, 16(2), 149–160. https://doi.org/10.1038/cgt.2008.62

72.

Zhong, J., Yang, X., Chen, J., He, K., Gao, X., Wu, X., … Zhang, N. (2022). Circular EZH2-encoded EZH2–92aa mediates immune evasion in glioblastoma via inhibition of surface NKG2D ligands. Nature Communications, 13(1), 4795. https://doi.org/10.1038/s41467-022-32311-2

73.

Ruggeri, L., Capanni, M., Urbani, E., Perruccio, K., Shlomchik, W. D., Tosti, A., … Velardi, A. (2002). Effectiveness of donor natural killer cell alloreactivity in mismatched hematopoietic transplants. Science (New York, N.Y.), 295(5562), 2097–2100. https://doi.org/10.1126/science.1068440

74.

Kim, H., Kim, J., Sa, J. K., Ryu, B.-K., Park, K.-J., Kim, J., … Kang, S.-H. (2022). Calcipotriol, a synthetic Vitamin D analog, promotes antitumor immunity via CD4+T-dependent CTL/NK cell activation. Biomedicine & Pharmacotherapy = Biomedecine & Pharmacotherapie, 154, 113553. https://doi.org/10.1016/j.biopha.2022.113553

75.

Salazar, N., Carlson, J. C., Huang, K., Zheng, Y., Oderup, C., Gross, J., … Zabel, B. A. (2018). A chimeric antibody against ACKR3/CXCR7 in combination with TMZ activates immune responses and extends survival in mouse GBM models. Molecular Therapy: The Journal of the American Society of Gene Therapy, 26(5), 1354–1365. https://doi.org/10.1016/j.ymthe.2018.02.030

76.

Glumac, P. M., & LeBeau, A. M. (2018). The role of CD133 in cancer: A concise review. Clinical and Translational Medicine, 7(1), 18. https://doi.org/10.1186/s40169-018-0198-1CrossRefPubMedPubMedCentral

77.

Srivastava, S., Jackson, C., Kim, T., Choi, J., & Lim, M. (2019). A characterization of dendritic cells and their role in immunotherapy in glioblastoma: From preclinical studies to clinical trials. Cancers, 11(4), 537. https://doi.org/10.3390/cancers11040537CrossRefPubMedPubMedCentral

78.

Friedrich, M., Hahn, M., Michel, J., Sankowski, R., Kilian, M., Kehl, N., … Bunse, L. (2023). Dysfunctional dendritic cells limit antigen-specific T cell response in glioma. Neuro-Oncology, 25(2), 263–276. https://doi.org/10.1093/neuonc/noac138

79.

Xu, L. W., Chow, K. K. H., Lim, M., & Li, G. (2014). Current vaccine trials in glioblastoma: A review. Journal of Immunology Research, 2014, 796856. https://doi.org/10.1155/2014/796856CrossRefPubMedPubMedCentral

80.

Pombo Antunes, A. R., Scheyltjens, I., Duerinck, J., Neyns, B., Movahedi, K., & Van Ginderachter, J. A. (2020). Understanding the glioblastoma immune microenvironment as basis for the development of new immunotherapeutic strategies. eLife, 9, e52176. https://doi.org/10.7554/eLife.52176

81.

Wang, H., Zhou, H., Xu, J., Lu, Y., Ji, X., Yao, Y., … Wan, J. (2021). Different T-cell subsets in glioblastoma multiforme and targeted immunotherapy. Cancer Letters, 496, 134–143. https://doi.org/10.1016/j.canlet.2020.09.028

82.

Tang, O. Y., Binder, Z. A., O’Rourke, D. M., & Bagley, S. J. (2023). Optimizing CAR-T therapy for glioblastoma. Molecular Diagnosis & Therapyhttps://doi.org/10.1007/s40291-023-00671-0

83.

Dhatchinamoorthy, K., Colbert, J. D., & Rock, K. L. (2021). Cancer immune evasion through loss of MHC class I antigen presentation. Frontiers in Immunology, 12, 636568. https://doi.org/10.3389/fimmu.2021.636568CrossRefPubMedPubMedCentral

84.

Nduom, E. K., Weller, M., & Heimberger, A. B. (2015). Immunosuppressive mechanisms in glioblastoma. Neuro-Oncology, 17 Suppl 7(Suppl 7), vii9–vii14. https://doi.org/10.1093/neuonc/nov151

85.

Silver, A., Feier, D., Ghosh, T., Rahman, M., Huang, J., Sarkisian, M. R., & Deleyrolle, L. P. (2022). Heterogeneity of glioblastoma stem cells in the context of the immune microenvironment and geospatial organization. Frontiers in Oncology, 12, 1022716. https://doi.org/10.3389/fonc.2022.1022716CrossRefPubMedPubMedCentral

86.

van Hooren, L., Handgraaf, S. M., Kloosterman, D. J., Karimi, E., van Mil, L. W. H. G., Gassama, A. A., … Akkari, L. (2023). CD103+ regulatory T cells underlie resistance to radio-immunotherapy and impair CD8+ T cell activation in glioblastoma. Nature Cancer, 4(5), 665–681. https://doi.org/10.1038/s43018-023-00547-6

87.

Yoshioka, S., Ikeda, T., Fukuchi, S., Kawai, Y., Ohta, K., Murakami, H., … Asai, A. (2022). Identification and characterization of a novel dual inhibitor of indoleamine 2,3-dioxygenase 1 and tryptophan 2,3-dioxygenase. International journal of tryptophan research: IJTR, 15, 11786469221138456. https://doi.org/10.1177/11786469221138456

88.

Zhang, Y., Jin, T., Dou, Z., Wei, B., Zhang, B., & Sun, C. (2022). The dual role of the CD95 and CD95L signaling pathway in glioblastoma. Frontiers in Immunology, 13, 1029737. https://doi.org/10.3389/fimmu.2022.1029737CrossRefPubMedPubMedCentral

89.

Ross, J. L., Velazquez Vega, J., Plant, A., MacDonald, T. J., Becher, O. J., & Hambardzumyan, D. (2021). Tumour immune landscape of paediatric high-grade gliomas. Brain: A Journal of Neurology, 144(9), 2594–2609. https://doi.org/10.1093/brain/awab155

90.

Hwang, E. I., Sayour, E. J., Flores, C. T., Grant, G., Wechsler-Reya, R., Hoang-Minh, L. B., … Pollack, I. F. (2022). The current landscape of immunotherapy for pediatric brain tumors. Nature Cancer, 3(1), 11–24. https://doi.org/10.1038/s43018-021-00319-0

91.

Griesinger, A. M., Birks, D. K., Donson, A. M., Amani, V., Hoffman, L. M., Waziri, A., … Foreman, N. K. (2013). Characterization of distinct immunophenotypes across pediatric brain tumor types. Journal of Immunology (Baltimore, Md.: 1950), 191(9), 4880–4888. https://doi.org/10.4049/jimmunol.1301966

92.

Robinson, M. H., Vasquez, J., Kaushal, A., MacDonald, T. J., Velázquez Vega, J. E., Schniederjan, M., & Dhodapkar, K. (2020). Subtype and grade-dependent spatial heterogeneity of T-cell infiltration in pediatric glioma. Journal for Immunotherapy of Cancer, 8(2), e001066. https://doi.org/10.1136/jitc-2020-001066CrossRefPubMedPubMedCentral

93.

Lieberman, N. A. P., DeGolier, K., Kovar, H. M., Davis, A., Hoglund, V., Stevens, J., … Crane, C. A. (2019). Characterization of the immune microenvironment of diffuse intrinsic pontine glioma: Implications for development of immunotherapy. Neuro-Oncology, 21(1), 83–94. https://doi.org/10.1093/neuonc/noy145

94.

Lin, G. L., Nagaraja, S., Filbin, M. G., Suvà, M. L., Vogel, H., & Monje, M. (2018). Non-inflammatory tumor microenvironment of diffuse intrinsic pontine glioma. Acta Neuropathologica Communications, 6(1), 51. https://doi.org/10.1186/s40478-018-0553-xCrossRefPubMedPubMedCentral

95.

Lei, M. M. L., & Lee, T. K. W. (2021). Cancer stem cells: Emerging key players in immune evasion of cancers. Frontiers in Cell and Developmental Biology, 9, 692940. https://doi.org/10.3389/fcell.2021.692940CrossRefPubMedPubMedCentral

96.

Zhu, X., Chen, H.-H., Gao, C.-Y., Zhang, X.-X., Jiang, J.-X., Zhang, Y., … Chen, Z.-G. (2020). Energy metabolism in cancer stem cells. World Journal of Stem Cells, 12(6), 448–461. https://doi.org/10.4252/wjsc.v12.i6.448

97.

Peiris-Pagès, M., Martinez-Outschoorn, U. E., Pestell, R. G., Sotgia, F., & Lisanti, M. P. (2016). Cancer stem cell metabolism. Breast Cancer Research, 18(1), 55. https://doi.org/10.1186/s13058-016-0712-6CrossRefPubMedPubMedCentral

98.

Kaur, J., & Bhattacharyya, S. (2021). Cancer stem cells: Metabolic characterization for targeted cancer therapy. Frontiers in Oncology, 11. Retrieved from https://www.frontiersin.org/articles/https://doi.org/10.3389/fonc.2021.756888

99.

Yu, L., Ji, K.-Y., Zhang, J., Xu, Y., Ying, Y., Mai, T., … Xu, Y. (2019). Core pluripotency factors promote glycolysis of human embryonic stem cells by activating GLUT1 enhancer. Protein & Cell, 10(9), 668–680. https://doi.org/10.1007/s13238-019-0637-9

100.

Wang, Z.-H., Peng, W.-B., Zhang, P., Yang, X.-P., & Zhou, Q. (2021). Lactate in the tumour microenvironment: From immune modulation to therapy. eBioMedicine, 73. https://doi.org/10.1016/j.ebiom.2021.103627

101.

Lim, K. S., Lim, K. J., Price, A. C., Orr, B. A., Eberhart, C. G., & Bar, E. E. (2014). Inhibition of monocarboxylate transporter-4 depletes stem-like glioblastoma cells and inhibits HIF transcriptional response in a lactate-independent manner. Oncogene, 33(35), 4433–4441. https://doi.org/10.1038/onc.2013.390CrossRefPubMed

102.

Goidts, V., Bageritz, J., Puccio, L., Nakata, S., Zapatka, M., Barbus, S., … Radlwimmer, B. (2012). RNAi screening in glioma stem-like cells identifies PFKFB4 as a key molecule important for cancer cell survival. Oncogene, 31(27), 3235–3243. https://doi.org/10.1038/onc.2011.490

103.

Ye, X.-Q., Li, Q., Wang, G.-H., Sun, F.-F., Huang, G.-J., Bian, X.-W., … Qian, G.-S. (2011). Mitochondrial and energy metabolism-related properties as novel indicators of lung cancer stem cells. International Journal of Cancer, 129(4), 820–831. https://doi.org/10.1002/ijc.25944

104.

Yasuda, T., Ishimoto, T., & Baba, H. (2021). Conflicting metabolic alterations in cancer stem cells and regulation by the stromal niche. Regenerative Therapy, 17, 8–12. https://doi.org/10.1016/j.reth.2021.01.005CrossRefPubMedPubMedCentral

105.

Sriramkumar, S., Sood, R., Huntington, T. D., Ghobashi, A. H., Vuong, T. T., Metcalfe, T. X., … O’Hagan, H. M. (2022). Platinum-induced mitochondrial OXPHOS contributes to cancer stem cell enrichment in ovarian cancer. Journal of Translational Medicine, 20(1), 246. https://doi.org/10.1186/s12967-022-03447-y

106.

Janiszewska, M., Suvà, M. L., Riggi, N., Houtkooper, R. H., Auwerx, J., Clément-Schatlo, V., … Stamenkovic, I. (2012). Imp2 controls oxidative phosphorylation and is crucial for preserving glioblastoma cancer stem cells. Genes & Development, 26(17), 1926–1944. https://doi.org/10.1101/gad.188292.112

107.

Sancho, P., Burgos-Ramos, E., Tavera, A., Bou Kheir, T., Jagust, P., Schoenhals, M., … Heeschen, C. (2015). MYC/PGC-1α balance determines the metabolic phenotype and plasticity of pancreatic cancer stem cells. Cell Metabolism, 22(4), 590–605. https://doi.org/10.1016/j.cmet.2015.08.015

108.

Vlashi, E., Lagadec, C., Vergnes, L., Matsutani, T., Masui, K., Poulou, M., … Pajonk, F. (2011). Metabolic state of glioma stem cells and nontumorigenic cells. Proceedings of the National Academy of Sciences, 108(38), 16062–16067. https://doi.org/10.1073/pnas.1106704108

109.

Jiang, N., Xie, B., Xiao, W., Fan, M., Xu, S., Duan, Y., … Li, J. J. (2022). Fatty acid oxidation fuels glioblastoma radioresistance with CD47-mediated immune evasion. Nature Communications, 13(1), 1511. https://doi.org/10.1038/s41467-022-29137-3

110.

Zhu, Y., Lin, X., Zhou, X., Prochownik, E. V., Wang, F., & Li, Y. (2022). Posttranslational control of lipogenesis in the tumor microenvironment. Journal of Hematology & Oncology, 15(1), 120. https://doi.org/10.1186/s13045-022-01340-1CrossRef

111.

Ferguson, L. P., Diaz, E., & Reya, T. (2021). The role of the microenvironment and immune system in regulating stem cell fate in cancer. Trends in Cancer, 7(7), 624–634. https://doi.org/10.1016/j.trecan.2020.12.014CrossRefPubMedPubMedCentral

112.

Hirsch, H. A., Iliopoulos, D., & Struhl, K. (2013). Metformin inhibits the inflammatory response associated with cellular transformation and cancer stem cell growth. Proceedings of the National Academy of Sciences of the United States of America, 110(3), 972–977. https://doi.org/10.1073/pnas.1221055110CrossRefPubMed

113.

Johnson, D. E., O’Keefe, R. A., & Grandis, J. R. (2018). Targeting the IL-6/JAK/STAT3 signalling axis in cancer. Nature Reviews. Clinical Oncology, 15(4), 234–248. https://doi.org/10.1038/nrclinonc.2018.8CrossRefPubMedPubMedCentral

114.

Park, H.-B., Paik, D.-J., Jang, E., Hong, S., & Youn, J. (2004). Acquisition of anergic and suppressive activities in transforming growth factor-beta-costimulated CD4+CD25- T cells. International Immunology, 16(8), 1203–1213. https://doi.org/10.1093/intimm/dxh123CrossRefPubMed

115.

Dennis, K. L., Blatner, N. R., Gounari, F., & Khazaie, K. (2013). Current status of interleukin-10 and regulatory T-cells in cancer. Current Opinion in Oncology, 25(6), 637–645. https://doi.org/10.1097/CCO.0000000000000006CrossRefPubMedPubMedCentral

116.

Park, S.-J., Nakagawa, T., Kitamura, H., Atsumi, T., Kamon, H., Sawa, S.-I., … Hirano, T. (2004). IL-6 regulates in vivo dendritic cell differentiation through STAT3 activation. Journal of Immunology (Baltimore, Md.: 1950), 173(6), 3844–3854. https://doi.org/10.4049/jimmunol.173.6.3844

117.

Ozawa, Y., Yamamuro, S., Sano, E., Tatsuoka, J., Hanashima, Y., Yoshimura, S., … Yoshino, A. (2020). Indoleamine 2,3-dioxygenase 1 is highly expressed in glioma stem cells. Biochemical and Biophysical Research Communications, 524(3), 723–729. https://doi.org/10.1016/j.bbrc.2020.01.148

118.

Ju, J.-M., Nam, G., Lee, Y.-K., Jung, M., Chang, H., Kim, W., … Choi, E. Y. (2021). IDO1 scavenges reactive oxygen species in myeloid-derived suppressor cells to prevent graft-versus-host disease. Proceedings of the National Academy of Sciences, 118(10), e2011170118. https://doi.org/10.1073/pnas.2011170118

119.

Opitz, C. A., Somarribas Patterson, L. F., Mohapatra, S. R., Dewi, D. L., Sadik, A., Platten, M., & Trump, S. (2020). The therapeutic potential of targeting tryptophan catabolism in cancer. British Journal of Cancer, 122(1), 30–44. https://doi.org/10.1038/s41416-019-0664-6CrossRefPubMed

120.

Stone, T. W., & Williams, R. O. (2023). Modulation of T cells by tryptophan metabolites in the kynurenine pathway. Trends in Pharmacological Sciences, 44(7), 442–456. https://doi.org/10.1016/j.tips.2023.04.006CrossRefPubMed

121.

Lužnik, Z., Anchouche, S., Dana, R., & Yin, J. (2020). Regulatory T cells in angiogenesis. Journal of Immunology (Baltimore, Md.: 1950), 205(10), 2557–2565. https://doi.org/10.4049/jimmunol.2000574

122.

Liu, C., Chikina, M., Deshpande, R., Menk, A. V., Wang, T., Tabib, T., … Vignali, D. A. A. (2019). Treg cells promote the SREBP1-dependent metabolic fitness of tumor-promoting macrophages via repression of CD8+ T cell-derived interferon-γ. Immunity, 51(2), 381–397.e6. https://doi.org/10.1016/j.immuni.2019.06.017

123.

Da-Veiga, M.-A., Coppieters, N., Lombard, A., Rogister, B., Neirinckx, V., & Piette, C. (2023). Comprehensive profiling of stem-like features in pediatric glioma cell cultures and their relation to the subventricular zone. Acta Neuropathologica Communications, 11(1), 96. https://doi.org/10.1186/s40478-023-01586-xCrossRefPubMedPubMedCentral

124.

Thirant, C., Bessette, B., Varlet, P., Puget, S., Cadusseau, J., Dos Reis Tavares, S., … Junier, M.-P. (2011). Clinical relevance of tumor cells with stem-like properties in pediatric brain tumors. PLoS ONE, 6(1), e16375. https://doi.org/10.1371/journal.pone.0016375

125.

De Wet, L., Williams, A., Gillard, M., Kregel, S., Lamperis, S., Gutgesell, L. C., … Vander Griend, D. J. (2022). SOX2 mediates metabolic reprogramming of prostate cancer cells. Oncogene, 41(8), 1190–1202. https://doi.org/10.1038/s41388-021-02157-x

126.

Da-Veiga, M.-A., Rogister, B., Lombard, A., Neirinckx, V., & Piette, C. (2022). Glioma stem cells in pediatric high-grade gliomas: From current knowledge to future perspectives. Cancers, 14(9), 2296. https://doi.org/10.3390/cancers14092296CrossRefPubMedPubMedCentral

127.

Neradil, J., & Veselska, R. (2015). Nestin as a marker of cancer stem cells. Cancer Science, 106(7), 803–811. https://doi.org/10.1111/cas.12691CrossRefPubMedPubMedCentral

128.

Surowiec, R. K., Ferris, S. F., Apfelbaum, A., Espinoza, C., Mehta, R. K., Monchamp, K., … Galban, S. (2021). Transcriptomic analysis of diffuse intrinsic pontine glioma (DIPG) identifies a targetable ALDH-positive subset of highly tumorigenic cancer stem-like cells. Molecular Cancer Research, 19(2), 223–239. https://doi.org/10.1158/1541-7786.MCR-20-0464

129.

Murakami, T., Nakazawa, T., Natsume, A., Nishimura, F., Nakamura, M., Matsuda, R., … Nakase, H. (2018). Novel human NK cell line carrying CAR targeting EGFRvIII induces antitumor effects in glioblastoma cells. Anticancer Research, 38(9), 5049–5056. https://doi.org/10.21873/anticanres.12824

130.

Khan, M., Arooj, S., & Wang, H. (2020). NK cell-based immune checkpoint inhibition. Frontiers in Immunology, 11, 167. https://doi.org/10.3389/fimmu.2020.00167CrossRefPubMedPubMedCentral

131.

Sönmez, C., Wölfer, J., Holling, M., Brokinkel, B., Stummer, W., Wiendl, H., … Grauer, O. M. (2022). Blockade of inhibitory killer cell immunoglobulin-like receptors and IL-2 triggering reverses the functional hypoactivity of tumor-derived NK-cells in glioblastomas. Scientific Reports, 12(1), 6769. https://doi.org/10.1038/s41598-022-10680-4

132.

Weiss, T., Schneider, H., Silginer, M., Steinle, A., Pruschy, M., Polić, B., … Roth, P. (2018). NKG2D-dependent antitumor effects of chemotherapy and radiotherapy against glioblastoma. Clinical Cancer Research: An Official Journal of the American Association for Cancer Research, 24(4), 882–895. https://doi.org/10.1158/1078-0432.CCR-17-1766

133.

Pawlowski, K. D., Duffy, J. T., Tiwari, A., Zannikou, M., & Balyasnikova, I. V. (2023). Bi-specific killer cell engager enhances NK cell activity against interleukin-13 receptor alpha-2 positive gliomas. Cells, 12(13), 1716. https://doi.org/10.3390/cells12131716CrossRefPubMedPubMedCentral

134.

Datsi, A., & Sorg, R. V. (2021). Dendritic cell vaccination of glioblastoma: Road to success or dead end. Frontiers in Immunology, 12, 770390. https://doi.org/10.3389/fimmu.2021.770390CrossRefPubMedPubMedCentral

135.

Rojas, L. A., Sethna, Z., Soares, K. C., Olcese, C., Pang, N., Patterson, E., … Balachandran, V. P. (2023). Personalized RNA neoantigen vaccines stimulate T cells in pancreatic cancer. Nature, 618(7963), 144–150. https://doi.org/10.1038/s41586-023-06063-y

136.

Catania, G., Rodella, G., Vanvarenberg, K., Préat, V., & Malfanti, A. (2023). Combination of hyaluronic acid conjugates with immunogenic cell death inducer and CpG for glioblastoma local chemo-immunotherapy elicits an immune response and induces long-term survival. Biomaterials, 294, 122006. https://doi.org/10.1016/j.biomaterials.2023.122006CrossRefPubMed

137.

Segura-Collar, B., Hiller-Vallina, S., de Dios, O., Caamaño-Moreno, M., Mondejar-Ruescas, L., Sepulveda-Sanchez, J. M., & Gargini, R. (2023). Advanced immunotherapies for glioblastoma: Tumor neoantigen vaccines in combination with immunomodulators. Acta Neuropathologica Communications, 11(1), 79. https://doi.org/10.1186/s40478-023-01569-yCrossRefPubMedPubMedCentral

138.

Xun, Y., Yang, H., Kaminska, B., & You, H. (2021). Toll-like receptors and toll-like receptor-targeted immunotherapy against glioma. Journal of Hematology & Oncology, 14(1), 176. https://doi.org/10.1186/s13045-021-01191-2CrossRef

139.

Parker, S., McDowall, C., Sanchez-Perez, L., Osorio, C., Duncker, P. C., Briley, A., … Chandramohan, V. (2023). Immunotoxin-αCD40 therapy activates innate and adaptive immunity and generates a durable antitumor response in glioblastoma models. Science Translational Medicine, 15(682), eabn5649. https://doi.org/10.1126/scitranslmed.abn5649

140.

Didenko, V. V., Ngo, H. N., Minchew, C., & Baskin, D. S. (2002). Apoptosis of T lymphocytes invading glioblastomas multiforme: A possible tumor defense mechanism. Journal of Neurosurgery, 96(3), 580–584. https://doi.org/10.3171/jns.2002.96.3.0580CrossRefPubMed

141.

Kollis, P. M., Ebert, L. M., Toubia, J., Bastow, C. R., Ormsby, R. J., Poonnoose, S. I., … Gargett, T. (2022). Characterising distinct migratory profiles of infiltrating T-cell subsets in human glioblastoma. Frontiers in Immunology, 13, 850226. https://doi.org/10.3389/fimmu.2022.850226

142.

Chen, D., Varanasi, S. K., Hara, T., Traina, K., Sun, M., McDonald, B., … Kaech, S. M. (2023). CTLA-4 blockade induces a microglia-Th1 cell partnership that stimulates microglia phagocytosis and anti-tumor function in glioblastoma. Immunity, 56(9), 2086–2104.e8. https://doi.org/10.1016/j.immuni.2023.07.015

143.

Amoozgar, Z., Kloepper, J., Ren, J., Tay, R. E., Kazer, S. W., Kiner, E., … Jain, R. K. (2021). Targeting Treg cells with GITR activation alleviates resistance to immunotherapy in murine glioblastomas. Nature Communications, 12(1), 2582. https://doi.org/10.1038/s41467-021-22885-8

144.

Kesarwani, P., Prabhu, A., Kant, S., Kumar, P., Graham, S. F., Buelow, K. L., … Chinnaiyan, P. (2018). Tryptophan metabolism contributes to radiation-induced immune checkpoint reactivation in glioblastoma. Clinical Cancer Research: An Official Journal of the American Association for Cancer Research, 24(15), 3632–3643. https://doi.org/10.1158/1078-0432.CCR-18-0041

145.

Ahluwalia, M. S., Reardon, D. A., Abad, A. P., Curry, W. T., Wong, E. T., Belal, A., … Fenstermaker, R. (2019). SurVaxM with standard therapy in newly diagnosed glioblastoma: Phase II trial update. Journal of Clinical Oncology, 37(15_suppl), 2016–2016. https://doi.org/10.1200/JCO.2019.37.15_suppl.2016

146.

Fenstermaker, R. A., Ciesielski, M. J., Qiu, J., Yang, N., Frank, C. L., Lee, K. P., … Hutson, A. D. (2016). Clinical study of a survivin long peptide vaccine (SurVaxM) in patients with recurrent malignant glioma. Cancer Immunology, Immunotherapy, 65(11), 1339–1352. https://doi.org/10.1007/s00262-016-1890-x

147.

Flores, C., Wildes, T., Dean, B. D., Moore, G., Drake, J., Abraham, R., … Mitchell, D. (2019). Massive clonal expansion of medulloblastoma-specific T cells during adoptive cellular therapy. Science Advances, 5(11), eaav9879. https://doi.org/10.1126/sciadv.aav9879

148.

Choi, B. D., Kuan, C.-T., Cai, M., Archer, G. E., Mitchell, D. A., Gedeon, P. C., … Sampson, J. H. (2013). Systemic administration of a bispecific antibody targeting EGFRvIII successfully treats intracerebral glioma. Proceedings of the National Academy of Sciences, 110(1), 270–275. https://doi.org/10.1073/pnas.1219817110

149.

Choi, B. D., Yu, X., Castano, A. P., Bouffard, A. A., Schmidts, A., Larson, R. C., … Maus, M. V. (2019). CAR-T cells secreting BiTEs circumvent antigen escape without detectable toxicity. Nature Biotechnology, 37(9), 1049–1058. https://doi.org/10.1038/s41587-019-0192-1

150.

O’Rourke, D. M., Nasrallah, M. P., Desai, A., Melenhorst, J. J., Mansfield, K., Morrissette, J. J. D., … Maus, M. V. (2017). A single dose of peripherally infused EGFRvIII-directed CAR T cells mediates antigen loss and induces adaptive resistance in patients with recurrent glioblastoma. Science Translational Medicine, 9(399), eaaa0984. https://doi.org/10.1126/scitranslmed.aaa0984

151.

Mount, C. W., Majzner, R. G., Sundaresh, S., Arnold, E. P., Kadapakkam, M., Haile, S., … Mackall, C. L. (2018). Potent antitumor efficacy of anti-GD2 CAR T cells in H3-K27M+ diffuse midline gliomas. Nature Medicine, 24(5), 572–579. https://doi.org/10.1038/s41591-018-0006-x

152.

Majzner, R. G., Theruvath, J. L., Nellan, A., Heitzeneder, S., Cui, Y., Mount, C. W., … Mackall, C. L. (2019). CAR T cells targeting B7-H3, a pan-cancer antigen, demonstrate potent preclinical activity against pediatric solid tumors and brain tumors. Clinical Cancer Research, 25(8), 2560–2574. https://doi.org/10.1158/1078-0432.CCR-18-0432

153.

Patterson, J. D., Henson, J. C., Breese, R. O., Bielamowicz, K. J., & Rodriguez, A. (2020). CAR T cell therapy for pediatric brain tumors. Frontiers in Oncology, 10. Retrieved from https://www.frontiersin.org/journals/oncology/articles/https://doi.org/10.3389/fonc.2020.01582

154.

Sato, A., Sunayama, J., Okada, M., Watanabe, E., Seino, S., Shibuya, K., … Kitanaka, C. (2012). Glioma-initiating cell elimination by metformin activation of FOXO3 via AMPK. Stem Cells Translational Medicine, 1(11), 811–824. https://doi.org/10.5966/sctm.2012-0058

155.

Shibuya, K., Okada, M., Suzuki, S., Seino, M., Seino, S., Takeda, H., & Kitanaka, C. (2014). Targeting the facilitative glucose transporter GLUT1 inhibits the self-renewal and tumor-initiating capacity of cancer stem cells. Oncotarget, 6(2), 651–661.CrossRefPubMedCentral

156.

Zhao, H., Yan, C., Hu, Y., Mu, L., Liu, S., Huang, K., … Qin, J. (2020). Differentiated cancer cell-originated lactate promotes the self-renewal of cancer stem cells in patient-derived colorectal cancer organoids. Cancer Letters, 493, 236–244. https://doi.org/10.1016/j.canlet.2020.08.044

157.

Kim, S., & Singh, S. V. (2022). Monocarboxylate transporter 1 is a novel target for breast cancer stem like-cell inhibition by diallyl trisulfide. Molecular Carcinogenesis, 61(8), 752–763. https://doi.org/10.1002/mc.23415CrossRefPubMedPubMedCentral

158.

Longhitano, L., Vicario, N., Tibullo, D., Giallongo, C., Broggi, G., Caltabiano, R., … Li Volti, G. (2022). Lactate induces the expressions of MCT1 and HCAR1 to promote tumor growth and progression in glioblastoma. Frontiers in Oncology, 12, 871798. https://doi.org/10.3389/fonc.2022.871798

159.

Mohan, A. A., Tomaszewski, W. H., Haskell-Mendoza, A. P., Hotchkiss, K. M., Singh, K., Reedy, J. L., … Khasraw, M. (2021). Targeting immunometabolism in glioblastoma. Frontiers in Oncology, 11, 696402. https://doi.org/10.3389/fonc.2021.696402

Titel: Glioblastoma stem cell metabolism and immunity
verfasst von: Joseph Hawly
Micaela G. Murcar
Alejandro Schcolnik-Cabrera
Mark E. Issa
Publikationsdatum: 26.03.2024
Verlag: Springer US
Erschienen in: Cancer and Metastasis Reviews
Print ISSN: 0167-7659
Elektronische ISSN: 1573-7233
DOI: https://doi.org/10.1007/s10555-024-10183-w

Die Highlights vom Kongress des American College of Cardiology 2024

Springer Medizin

Glioblastoma stem cell metabolism and immunity

Abstract

Neu im Fachgebiet Onkologie

Alphablocker schützt vor Miktionsproblemen nach der Biopsie

Antikörper-Wirkstoff-Konjugat hält solide Tumoren in Schach

Mammakarzinom: Senken Statine das krebsbedingte Sterberisiko?

Labor, CT-Anthropometrie zeigen Risiko für Pankreaskrebs

Update Onkologie

Die Highlights vom Kongress des American College of Cardiology 2024

Springer Medizin

Abstract

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Neu im Fachgebiet Onkologie

Alphablocker schützt vor Miktionsproblemen nach der Biopsie

Antikörper-Wirkstoff-Konjugat hält solide Tumoren in Schach

Mammakarzinom: Senken Statine das krebsbedingte Sterberisiko?

Labor, CT-Anthropometrie zeigen Risiko für Pankreaskrebs

Update Onkologie